Y-mAbs Therapeutics, Inc. Share-based Payment Arrangement, Expense
Y-mAbs Therapeutics, Inc. reported Share-based Payment Arrangement, Expense of $2.90 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2025-08-08
- Y-mAbs Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-06-30 was $2.90M, a 15.59% decline year-over-year.
- Y-mAbs Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $3.34M, a 13.16% decline year-over-year.
- Y-mAbs Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2024-12-31 was $3.08M, a 1.41% decline year-over-year.
- Y-mAbs Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2024-09-30 was $4.20M, a 74.07% increase year-over-year.
- Y-mAbs Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $14.56M, a 0.73% increase from fiscal 2023.
- Y-mAbs Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $14.45M.
- Y-mAbs Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2021 was $19.33M, a 19.83% increase from fiscal 2020.
- Y-mAbs Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2020 was $16.14M, a 246.47% increase from fiscal 2019.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2025-06-30 | $2.90M 10-Q · filed 2025-08-08 | $6.24M 10-Q · filed 2025-08-08 | $9.32M derived: sum of 3 quarters · filed 2025-08-08 | $13.52M derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | $3.34M 10-Q · filed 2025-05-13 | $6.42M derived: sum of 2 quarters · filed 2025-05-13 | $10.61M derived: sum of 3 quarters · filed 2025-05-13 | $14.05M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $7.27M derived: sum of 2 quarters · filed 2025-03-04 | $10.71M derived: sum of 3 quarters · filed 2025-08-08 | $14.56M 10-K · filed 2025-03-04 |
| 2024-09-30 | $4.20M 10-Q · filed 2024-11-08 | $7.63M derived: sum of 2 quarters · filed 2025-08-08 | $11.48M 10-Q · filed 2024-11-08 | $14.60M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-06-30 | $3.44M 10-Q · filed 2025-08-08 | $7.29M 10-Q · filed 2025-08-08 | $10.41M derived: sum of 3 quarters · filed 2025-08-08 | $12.82M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $3.85M 10-Q · filed 2025-05-13 | $6.97M derived: sum of 2 quarters · filed 2025-05-13 | $9.38M derived: sum of 3 quarters · filed 2025-05-13 | $12.99M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $5.53M derived: sum of 2 quarters · filed 2025-03-04 | $9.15M derived: sum of 3 quarters · filed 2025-03-04 | $14.45M 10-K · filed 2025-03-04 |
| 2023-09-30 | $2.41M 10-Q · filed 2024-11-08 | $6.03M derived: sum of 2 quarters · filed 2024-11-08 | $11.33M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $3.62M 10-Q · filed 2024-08-12 | $8.92M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $5.30M 10-Q · filed 2024-05-07 | |||
| 2021-12-31 | $19.33M 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $16.14M 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $4.66M 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $1.38M 10-K · filed 2020-03-12 |